FuRong Investment
复容投资
elsewhere's corpus does not cover FuRong Investment as a primary subject. The only material that names it directly shows FuRong Investment as a follow-on investor in biotech deals: it re-upped in antibody-discovery CRO Biointron's nearly RMB 500 million Series B in 2022 , and participated in both the Pre-A and Series A rounds of Yinjia Bio, a high-end protein platform startup, in 2021 and 2023 respectively . Beyond these deal mentions, elsewhere has no profile of the fund's founding, size, strategy, or team.
AI-generated — may contain errors, please verify.
Coverage
Yinjia Biotech Closes Nearly RMB 100 Million Series A Round to Accelerate Buildout of Upstream Core Protein Ingredient Synthetic Biology Platform
Staying true to our mission as "protein craftsmen."
Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
Antibody discovery CRO **Baiying Biotech** closes nearly RMB 500 million Series B round
Specializing in antibody discovery CRO services to accelerate antibody drug development.
Yinjia Biotech Closes Pre-A Round, Advancing Its High-End Protein Platform to New Heights
Build a leading domestic "protein artisan" platform.
